FundingWatcher
Home / Startups / Top biotech startups / Biotech startups that raised Series B / Biotech startups that raised Series B in Massachusetts, United States

Biotech startups that raised Series B in Massachusetts, United States

Updated 16 Nov 2026

Reset
Biotech startups that raised Series B in Massachusetts, United States
One-time CSV
  • 168 funded companies, 152 with a website
  • Last round, amount, date, total raised and investors
  • CRM-ready CSV, 18 columns
  • Download right after payment
With founder contacts
Compiled to order
  • The full startup CSV, plus founders and executives
  • Up to 2 founders or CEOs per company, compiled to order
  • Name, job title and LinkedIn URL where found
  • Verified direct email per person
  • Startup CSV at once, contacts CSV by mail within 24 hours
Download right after paymentFree 10-row sampleSecure checkout by Stripe

Not sure about the data?

Download a free 10-row sample first. No account, no payment.

startups-biotech--series-b~massachusetts-united-states.csv168 rows × 18 columns
CompanyCityLast roundAmountDate
Superluminal MedicinesBostonSeries B$65.5M2026-09-03
SimnovaCambridgeSeries B$59.3M2026-08-18
Elemental MachinesCambridgeSeries B$5.7M2026-05-27
KytopenCambridgeSeries B$1.6M2026-04-07
Atavistik BioCambridgeSeries B$40.0M2026-03-05
Precede BiosciencesBostonSeries B$63.5M2026-01-12
Diagonal TherapeuticsWatertownSeries B$125.0M2026-01-08
Nocion TherapeuticsCambridgeSeries B$23.0M2026-01-07

8 rows of the CSV in 5 of its 18 columns.

168
Startups
$17.5B
Total raised
24
Funded in the last 12 months
$1.6B
Raised in the last 12 months

Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.

Newest rounds

26 of 168
26 rows
Company What they do Sector City Last round Amount Date Total raised Investors Employees Founded
Superluminal Medicines Superluminal Medicines develops small-molecule therapeutics by combining AI, biology, and chemistry. Artificial intelligence Boston Series B $65.5M 2026-09-03 $223.5M Insight Partners, RA Capital Management, NVentures 11 to 50 2022
Simnova Simnova Biotherapeutics develops CAR-based cell therapies for treating cancer. Biotech Cambridge Series B $59.3M 2026-08-18 $87.2M Oriza Seed Capital (Oriza Yuandian), Youshan Capital, PagodaTree Partners +1 51 to 100 2019
Elemental Machines Elemental Machines provides data-driven insights to improve research, laboratory operations, and manufacturing outcomes. Artificial intelligence Cambridge Series B $5.7M 2026-05-27 $66.5M Founders Fund, Tau Ventures, Rock Health Capital +2 11 to 50 2015
Kytopen Kytopen develops genome engineering platforms for cell therapy research and manufacturing. Biotech Cambridge Series B $1.6M 2026-04-07 $39.1M National Science Foundation, MassVentures, Alexandria Venture Investments +1 11 to 50 2017
Atavistik Bio Atavistik Bio develops precision allosteric small molecules to treat metabolic diseases and cancer. Biotech Cambridge Series B $40.0M 2026-03-05 $260.0M Lux Capital, The Column Group, Nextech Invest 11 to 50 2021
Precede Biosciences Precede Biosciences develops blood-based tests that reveal disease-defining transcriptional biology. Biotech Boston Series B $63.5M 2026-01-12 $140.5M Bristol-Myers Squibb, Lilly Asia Ventures, 5AM Ventures +2 11 to 50 2005
Diagonal Therapeutics Diagonal Therapeutics develops targeted therapies for cancer and genetic diseases. Biotech Watertown Series B $125.0M 2026-01-08 $253.0M Lightspeed Venture Partners, RA Capital Management, Atlas Venture +1 11 to 50 2022
Nocion Therapeutics Nocion Therapeutics develops pharmaceuticals to treat conditions arising from neurogenic inflammation. Biotech Cambridge Series B $23.0M 2026-01-07 $134.0M Canaan Partners, F-Prime, OUP (Osage University Partners) +2 11 to 50 2017
Myrtelle Myrtelle is a gene therapy company that runs clinical trials for rare monogenetic disorders. Biotech Wakefield Series B $30.5M 2025-12-23 $57.6M Panacea Venture 11 to 50 2020
Manifold Manifold provides machine learning tools that analyze operational data to support industrial and energy decisions. Artificial intelligence Newton Series B $18.0M 2025-12-18 $40.5M TQ Ventures, Calibrate Ventures, SK Ventures +1 101 to 250 2016
Sanegene Bio Sanegene Bio develops an RNAi drug discovery platform aimed at unmet clinical needs. Biotech Woburn Series B $110.0M 2025-12-08 $240.0M Shenzhen Capital Group, Qiming Venture Partners, Northern Light Venture Capital +1 51 to 100 2021
Kailera Therapeutics Kailera Therapeutics develops injectable and oral therapies for chronic weight management. Biotech Waltham Series B $600.0M 2025-10-14 $1.0B Atlas Venture, Bain Capital Life Sciences, RTW Investments 101 to 250 2024
AIRNA AIRNA develops RNA editing technologies to create medicines for various diseases. Biotech Cambridge Series B $155.0M 2025-04-01 $245.0M ARCH Venture Partners, Alexandria Venture Investments, Forbion Capital Partners +2 51 to 100 2021
Stellaromics Stellaromics develops 3D in situ multi-omic analysis technology for biotechnology research. Biotech Natick Series B $80.0M 2025-02-11 $105.0M Plaisance Capital Management 11 to 50 2022
VideaHealth VideaHealth offers dentistAI software that automatically detects pathologies in dental imaging to help dentists avoid missed diagnoses. Biotech Boston Series B $40.0M 2025-01-28 $66.5M Spark Capital, Zetta Venture Partners, Pillar VC +2 51 to 100 2018
Seismic Therapeutic Seismic Therapeutic applies machine learning to develop drugs for immunology. Biotech Watertown Series B $25.0M 2024-09-12 $247.0M Lightspeed Venture Partners, Gaingels, Bessemer Venture Partners +2 51 to 100 2020
Cardurion Pharmaceuticals Cardurion Pharmaceuticals develops cardiovascular therapeutics for heart failure and related diseases. Biotech Boston Series B $260.0M 2024-07-16 $603.1M New Enterprise Associates, Google Ventures, Fidelity +1 11 to 50 2017
Qlaris Bio Qlaris Bio develops first-in-class therapies for serious and debilitating eye diseases. Biotech Wellesley Series B $24.0M 2024-04-22 $49.0M Correlation Ventures, Canaan Partners, New Leaf Venture Partners +1 1 to 10 2019
NextPoint Therapeutics NextPoint Therapeutics develops therapeutics to treat cancer patients as a clinical-stage biotechnology company. Biotech Cambridge Series B $42.5M 2024-02-14 $122.5M Invus, Leaps by Bayer, Catalio Capital Management +2 51 to 100 2020
Comanche Biopharma Comanche Biopharma works to make pregnancies around the world safer. Biotech Concord Series B $75.0M 2024-01-17 $111.1M New Enterprise Associates, Google Ventures, F-Prime +2 11 to 50 2020
ROME Therapeutics ROME Therapeutics develops therapies for cancer and autoimmune diseases by targeting the repeatome. Biotech Cambridge Series B $72.0M 2023-09-12 $199.0M Andreessen Horowitz, Google Ventures, Alexandria Venture Investments +2 11 to 50 2020
Mariana Oncology Mariana Oncology conducts biotechnology research in the oncology field. Biotech Watertown Series B $175.0M 2023-09-07 $250.0M RA Capital Management, Forbion Capital Partners, Surveyor Capital +1 11 to 50 2021
Asimov Asimov uses artificial intelligence to build tools for designing and manufacturing therapeutics. Artificial intelligence Boston Series B $175.0M 2023-01-05 $205.0M Andreessen Horowitz, DCVC, Fidelity +2 101 to 250 2017
InsideTracker InsideTracker provides a platform that analyzes and tracks key biochemical and physiological markers. Biotech Cambridge Series B $15.0M 2022-09-06 $18.2M OurCrowd, MassVentures, Puget Sound Venture Club +2 11 to 50 2009
BostonGene Unicorn BostonGene provides biomedical software for analyzing patients and personalizing cancer therapy. Biotech Waltham Series B $150.0M 2022-04-06 $200.0M Japan Industrial Partners 251 to 500 2015
Phylos Phylos discovers and develops novel biopharmaceutical products. Biotech Lexington Series B $25.0M 2001-01-01 Sprout Group, Three Arch Partners, Lone Pine Capital

Table 1. Biotech startups that raised Series B in Massachusetts, United States: the 26 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 168.

Largest rounds

Last 12 months
10 rows
# Company What they do Sector City Last round Amount Date Total raised Investors Employees Founded
1 Diagonal Therapeutics Diagonal Therapeutics develops targeted therapies for cancer and genetic diseases. Biotech Watertown Series B $125.0M 2026-01-08 $253.0M Lightspeed Venture Partners, RA Capital Management, Atlas Venture +1 11 to 50 2022
2 Sanegene Bio Sanegene Bio develops an RNAi drug discovery platform aimed at unmet clinical needs. Biotech Woburn Series B $110.0M 2025-12-08 $240.0M Shenzhen Capital Group, Qiming Venture Partners, Northern Light Venture Capital +1 51 to 100 2021
3 Superluminal Medicines Superluminal Medicines develops small-molecule therapeutics by combining AI, biology, and chemistry. Artificial intelligence Boston Series B $65.5M 2026-09-03 $223.5M Insight Partners, RA Capital Management, NVentures 11 to 50 2022
4 Precede Biosciences Precede Biosciences develops blood-based tests that reveal disease-defining transcriptional biology. Biotech Boston Series B $63.5M 2026-01-12 $140.5M Bristol-Myers Squibb, Lilly Asia Ventures, 5AM Ventures +2 11 to 50 2005
5 Simnova Simnova Biotherapeutics develops CAR-based cell therapies for treating cancer. Biotech Cambridge Series B $59.3M 2026-08-18 $87.2M Oriza Seed Capital (Oriza Yuandian), Youshan Capital, PagodaTree Partners +1 51 to 100 2019
6 Atavistik Bio Atavistik Bio develops precision allosteric small molecules to treat metabolic diseases and cancer. Biotech Cambridge Series B $40.0M 2026-03-05 $260.0M Lux Capital, The Column Group, Nextech Invest 11 to 50 2021
7 Myrtelle Myrtelle is a gene therapy company that runs clinical trials for rare monogenetic disorders. Biotech Wakefield Series B $30.5M 2025-12-23 $57.6M Panacea Venture 11 to 50 2020
8 Nocion Therapeutics Nocion Therapeutics develops pharmaceuticals to treat conditions arising from neurogenic inflammation. Biotech Cambridge Series B $23.0M 2026-01-07 $134.0M Canaan Partners, F-Prime, OUP (Osage University Partners) +2 11 to 50 2017
9 Manifold Manifold provides machine learning tools that analyze operational data to support industrial and energy decisions. Artificial intelligence Newton Series B $18.0M 2025-12-18 $40.5M TQ Ventures, Calibrate Ventures, SK Ventures +1 101 to 250 2016
10 Elemental Machines Elemental Machines provides data-driven insights to improve research, laboratory operations, and manufacturing outcomes. Artificial intelligence Cambridge Series B $5.7M 2026-05-27 $66.5M Founders Fund, Tau Ventures, Rock Health Capital +2 11 to 50 2015

Table 2. Biotech startups that raised Series B in Massachusetts, United States: the 10 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Most active investors

By companies backed
#InvestorTypeLocation CompaniesShare Funded, 12 monthsLatest
1 RA Capital Management Startup incubator Boston, United States 4 2% 2 Superluminal Medicines, Diagonal Therapeutics
2 Google Ventures Corporate venture arm San Francisco, United States 4 2%
3 Alexandria Venture Investments Venture capital firm Pasadena, United States 3 2% 1 Kytopen
4 Atlas Venture Venture capital firm Cambridge, United States 3 2% 1 Diagonal Therapeutics
5 F-Prime Venture capital firm Cambridge, United States 3 2% 1 Nocion Therapeutics
6 Andreessen Horowitz Venture capital firm Menlo Park, United States 3 2%
7 New Enterprise Associates Venture capital firm Menlo Park, United States 3 2%
8 Insight Partners Private equity firm New York, United States 2 1% 1 Superluminal Medicines
9 Digitalis Ventures Venture capital firm New York, United States 2 1% 1 Elemental Machines
10 KdT Ventures Venture capital firm Austin, United States 2 1% 1 Elemental Machines
11 MassVentures Venture capital firm Boston, United States 2 1% 1 Kytopen
12 National Science Foundation Entrepreneurship program Alexandria, United States 2 1% 1 Kytopen
13 Lilly Asia Ventures Venture capital firm Shanghai, China 2 1% 1 Precede Biosciences
14 Bristol-Myers Squibb Venture capital firm New York, United States 2 1% 1 Precede Biosciences
15 Lightspeed Venture Partners Venture capital firm Menlo Park, United States 2 1% 1 Diagonal Therapeutics

Table 3. Biotech startups that raised Series B in Massachusetts, United States: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Sectors

SectorsCompaniesShareTotal raised
Health care 157 93% $16.7B
Software 17 10% $1.5B
Artificial intelligence 9 5% $956.7M
Hardware 5 3% $194.0M
Commerce 1 1% $55.0M

Table 4. Biotech startups that raised Series B in Massachusetts, United States by sector. Source: FundingWatcher. Data as of 16 November 2026.

Funding stage

Funding stageCompaniesShareMedian last round
Series B 168 100% $41.3M

Table 5. Biotech startups that raised Series B in Massachusetts, United States by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.

Cities

CitiesCompaniesShare
Cambridge 68 40%
Boston 40 24%
Waltham 13 8%
Watertown 10 6%
Lexington 6 4%
Woburn 5 3%
Newton 3 2%
Burlington 3 2%
Natick 2 1%
Lowell 2 1%
Wakefield 1 1%
Framingham 1 1%

Table 6. Biotech startups that raised Series B in Massachusetts, United States by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.

Rounds by month

Rounds by monthCompaniesShareRaised
November 2026 1 4% $41.9M
October 2026 2 8% $285.0M
September 2026 1 4% $65.5M
August 2026 1 4% $59.3M
June 2026 3 12% $168.8M
May 2026 2 8% $127.7M
April 2026 1 4% $1.6M
March 2026 2 8% $117.0M
January 2026 6 25% $385.5M
December 2025 4 17% $278.5M
November 2025 1 4% $59.2M

Table 7. Biotech startups that raised Series B in Massachusetts, United States: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Most recent round by year

Most recent round by yearCompaniesShareRaised
2026 19 11% $1.3B
2025 19 11% $1.8B
2024 14 8% $972.0M
2023 20 12% $1.8B
2022 15 9% $1.3B
2021 15 9% $1.2B

Table 8. Biotech startups that raised Series B in Massachusetts, United States by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.

Founding year

Founding yearCompaniesShare
2023 or later 4 2%
2020 to 2022 30 18%
2015 to 2019 61 37%
2010 to 2014 28 17%
Before 2010 44 26%

Table 9. Biotech startups that raised Series B in Massachusetts, United States by founding year. Source: FundingWatcher. Data as of 16 November 2026.

Team size

Team sizeCompaniesShare
1 to 10 24 15%
11 to 50 85 52%
51 to 100 38 23%
101 to 250 12 7%
251 to 500 3 2%
501 to 1,000 1 1%
10,001 or more 1 1%

Table 10. Biotech startups that raised Series B in Massachusetts, United States by headcount. Source: FundingWatcher. Data as of 16 November 2026.

Method

Sources, fields and exclusions of both files: Method.

Questions

How many biotech startups in Massachusetts, United States whose last round is Series B are on the list?
168, in the file dated 16 November 2026. 24 of them closed their most recent round in the last 12 months.
What does the CSV contain?
One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
How much does the list cost?
$29 one-time for all 168 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
What arrives after payment?
At once: the CSV download link, on the page after payment and by mail.
Can I see rows before buying?
The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
How current is the data?
The file is dated 16 November 2026. The download link serves the current file each time it is opened.

Biotech startups that raised Series B in Massachusetts, United States: 168 rows, CSV, $29 one-time.

At once: the CSV download link, on the page after payment and by mail.

Columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.

With founder contacts: $199 one-time. List CSV right after payment; up to 2 verified founder or CEO emails per company compiled to order within 24 hours.

Not sure about the data?

Download a free 10-row sample first. No account, no payment.

Biotech at other stages in Massachusetts

Other sectors that raised Series B in Massachusetts

Cite: FundingWatcher, 168 biotech companies in Massachusetts, United States whose most recent round is Series B, 16 November 2026. https://fundingwatcher.com/startups/biotech/series-b/massachusetts-united-states/